Shin H, Yang W, Kim J, Chang H, Yoo J, Choi W
Heliyon. 2025; 11(4):e42539.
PMID: 40034272
PMC: 11874562.
DOI: 10.1016/j.heliyon.2025.e42539.
Krishnaraj J, Ueno S, Nakamura M, Tabata Y, Yamamoto T, Asano Y
Cancers (Basel). 2025; 17(4).
PMID: 40002205
PMC: 11853144.
DOI: 10.3390/cancers17040610.
Phuong D, Pirtz M, Ralston C, Cosgrove B, Schimenti J, Flesken-Nikitin A
Cancers (Basel). 2025; 17(4).
PMID: 40002199
PMC: 11852459.
DOI: 10.3390/cancers17040604.
Piki E, Dini A, Rantanen F, Bentz F, Paavolainen L, Barker H
Mol Ther Oncol. 2024; 32(4):200903.
PMID: 39634630
PMC: 11616607.
DOI: 10.1016/j.omton.2024.200903.
He B, Ma H, Yu H, Li D, Zhang L, Wang J
Front Oncol. 2024; 14:1484074.
PMID: 39529835
PMC: 11552305.
DOI: 10.3389/fonc.2024.1484074.
SOX17 expression in ovarian clear cell carcinoma.
Kodama D, Takenaka M, Saigo C, Azuma M, Hanamatsu Y, Isobe M
J Ovarian Res. 2024; 17(1):221.
PMID: 39529086
PMC: 11552154.
DOI: 10.1186/s13048-024-01549-3.
Pre-ciliated tubal epithelial cells are prone to initiation of high-grade serous ovarian carcinoma.
Flesken-Nikitin A, Ralston C, Fu D, De Micheli A, Phuong D, Harlan B
Nat Commun. 2024; 15(1):8641.
PMID: 39366996
PMC: 11452611.
DOI: 10.1038/s41467-024-52984-1.
Organoid modeling meets cancers of female reproductive tract.
Li J, Zhou M, Xie J, Chen J, Yang M, Ye C
Cell Death Discov. 2024; 10(1):410.
PMID: 39333482
PMC: 11437045.
DOI: 10.1038/s41420-024-02186-x.
Human papillomavirus infection of the fallopian tube as a potential risk factor for epithelial ovarian cancer.
Paradowska E, Hareza D, Kania K, Jarych D, Wilczynski M, Malinowski A
Sci Rep. 2024; 14(1):21602.
PMID: 39284893
PMC: 11405690.
DOI: 10.1038/s41598-024-72814-0.
MYC is Sufficient to Generate Mid-Life High-Grade Serous Ovarian and Uterine Serous Carcinomas in a p53-R270H Mouse Model.
Blackman A, Rees A, Bowers R, Jones C, Vaena S, Clark M
Cancer Res Commun. 2024; 4(9):2525-2538.
PMID: 39225558
PMC: 11425777.
DOI: 10.1158/2767-9764.CRC-24-0144.
lncRNA BC200 is processed into a stable Alu monomer.
Booy E, Gussakovsky D, Brown M, Shwaluk R, Nachtigal M, McKenna S
RNA. 2024; 30(11):1477-1494.
PMID: 39179355
PMC: 11482611.
DOI: 10.1261/rna.080152.124.
Correlation of PD-L1 expression with different clinico-pathological and immunohistochemical features of ovarian surface epithelial tumors.
Shalaby A, Shalaby O, Abdullah H, Boulassel M, Arafa M
Clin Transl Oncol. 2024; 27(2):699-705.
PMID: 39090421
PMC: 11782382.
DOI: 10.1007/s12094-024-03613-2.
Dormant origin firing promotes head-on transcription-replication conflicts at transcription termination sites in response to BRCA2 deficiency.
Goehring L, Keegan S, Lahiri S, Xia W, Kong M, Jimenez-Sainz J
Nat Commun. 2024; 15(1):4716.
PMID: 38830843
PMC: 11148086.
DOI: 10.1038/s41467-024-48286-1.
Bulk and single-cell transcriptome datasets of the mouse fetal and adult rete ovarii and surrounding tissues.
Anbarci D, ORourke R, Xiang Y, Peters D, Capel B, McKey J
Sci Data. 2024; 11(1):383.
PMID: 38615064
PMC: 11016079.
DOI: 10.1038/s41597-024-03227-x.
Spatial transcriptomics reveals discrete tumour microenvironments and autocrine loops within ovarian cancer subclones.
Denisenko E, de Kock L, Tan A, Beasley A, Beilin M, Jones M
Nat Commun. 2024; 15(1):2860.
PMID: 38570491
PMC: 10991508.
DOI: 10.1038/s41467-024-47271-y.
Organoids in ovarian cancer: a platform for disease modeling, precision medicine, and drug assessment.
Hu H, Sun C, Chen J, Li Z
J Cancer Res Clin Oncol. 2024; 150(3):146.
PMID: 38509422
PMC: 10955023.
DOI: 10.1007/s00432-024-05654-0.
Case report: diagnosis and treatment of advanced high-grade serous ovarian carcinoma aided by Ga-FAPI PET/MR scan.
Zhu M, Sun S, Huang L, Chen M, Cai J, Wang Z
Am J Nucl Med Mol Imaging. 2024; 14(1):72-77.
PMID: 38500744
PMC: 10944375.
Fallopian tube single cell analysis reveals myeloid cell alterations in high-grade serous ovarian cancer.
Brand J, Haro M, Lin X, Rimel B, McGregor S, Lawrenson K
iScience. 2024; 27(3):108990.
PMID: 38384837
PMC: 10879678.
DOI: 10.1016/j.isci.2024.108990.
Uterine washings as a novel method for early detection of ovarian cancer: Trials and tribulations.
Sia T, Yaari Z, Feiner R, Smith E, Da Cruz Paula A, Selenica P
Gynecol Oncol Rep. 2024; 51:101330.
PMID: 38356691
PMC: 10865230.
DOI: 10.1016/j.gore.2024.101330.
MYC is sufficient to generate mid-life high-grade serous ovarian and uterine serous carcinomas in a p53-R270H mouse model.
Blackman A, Rees A, Bowers R, Jones C, Vaena S, Clark M
bioRxiv. 2024; .
PMID: 38352443
PMC: 10862747.
DOI: 10.1101/2024.01.24.576924.